Diabetic Cardiomyopathy-From Basics through Diagnosis to Treatment

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Diseases

Background:

• Diabetic cardiomyopathy (DCM) is myocardial dysfunction in diabetic patients without other heart conditions.
• Poorly controlled diabetes, indicated by high glycated hemoglobin, strongly correlates with heart failure (HF).
• The incidence of HF in diabetic populations is rising, necessitating improved diagnosis and treatment.

Purpose of the Study:

• To highlight the significance of diagnosing and treating diabetic cardiomyopathy.
• To outline current therapeutic strategies for managing DCM and its cardiovascular complications.
• To explore emerging therapeutic avenues for DCM.

Main Methods:

• Review of existing literature and clinical studies, including the U.K. Prospective Diabetes Study (UKPDS).
• Analysis of the association between glycemic control (glycated hemoglobin) and heart failure incidence.
• Evaluation of pharmacological (antidiabetic, hypolipemic, HF therapies) and non-pharmacological interventions.

Main Results:

• Increasing glycated hemoglobin levels are linked to a higher risk of developing heart failure.
• Comprehensive treatment, including antidiabetic and hypolipemic agents alongside heart failure pharmacotherapy, mitigates DCM risks.
• Lifestyle modifications such as diet, exercise, and weight management are crucial for positive outcomes.

Conclusions:

• Integrated therapeutic approaches are vital for managing diabetic cardiomyopathy and reducing cardiovascular morbidity.
• Patient-led health-promoting behaviors significantly contribute to treatment success.
• Novel therapies like stem cells and miRNA show promise but require further investigation for DCM treatment.